Establishment of a transgenic cell line stably expressing human cytochrome P450 2C18 and identification of a CYP2C18 clone with exon 5 missing

World Journal of Gastroenterology

Volumn 8, Issue 5, 2002, Pages 888-892

  Zhu Ge, Jian ^a   Yu, Ying Nian ^a   Qian, Yu Li ^a   Li, Xin ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 2C18; ENZYME; HYDROXYTOLBUTAMIDE; RNA; TOLBUTAMIDE; TOLBUTAMIDE HYDROXYLASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CELL FRACTIONATION; CELL LINE; CHINESE HAMSTER; CLONING VECTOR; DNA SEQUENCE; DRUG METABOLISM; DRUG OXIDATION; ENZYME ACTIVITY; ENZYME ANALYSIS; EXON; GENE AMPLIFICATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER; LUNG ALVEOLUS CELL; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RECOMBINANT PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT; TRANSGENICS;

EID: 0036790505     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v8.i5.888     Document Type: Article

References (43)

1. Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001; 58: 737-747
2. Nelson DR. Cytochrome P450 and the individuality of species. Arch Biochem Biophys 1999; 369: 1-10
3. Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991; 30: 3247-3255
4. Richardson TH, Griffin KJ, Jung F, Raucy JL, Johnson EF. Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys 1997; 338: 157-164
5. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, Carrre N, Maurel P. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 2001; 29: 242-251
6. Liu XF, Zou SQ, Qiu FZ. Construction of HCV-core gene vector and its expression in cholangiocarcinoma. World J Gastroenterol 2002; 8: 135-138
7. Wu C, Zou QM, Guo H, Yuang XP, Zhang WJ, Lu DS, Mao XH. Expression, purification and immuno-characteristics of recombination UreB protein of H. pylori. World J Gastroenterol 2001; 7: 389-393
8. Li XJ, Wu JG, Si JL, Guo DW, Xu JP. High-level expression of human calmodulin in E.coli and its effects on cell proliferation. World J Gastroenterol 2000; 6: 588-592
9. Cheng J, Zhong YW, Liu Y, Dong J, Yang JZ, Chen JM. Cloning and sequence analysis of human genomic DNA of augmenter of liver regeneration. World J Gastroenterol 2000; 6: 275-277
10. Lu JG, Lin C, Huang ZQ, Wu JS, Fu M, Zhang XY, Liang X, Yao X, Wu M. Inhibitory effects of human cholangioc arcinoma cell line by recombinant adenovirus P16 with CDDP. Shijie Huaren Xiaohua Zazhi 2000; 8: 641-645
11. Qin XY, Shen KT, Zhang X, Cheng ZH, Xu XR, Han ZG. Establishment of an artificial β-cell line expressing insulin under the control of doxycycline. World J Gastroenterol 2002; 8: 367-370
12. Crespi CL, Miller VP. The use of heterologously expressed drug metabolizing enzymes-state of the art and prospects for the future. Pharmacol Therapeutics 1999; 84:121-131
13. Mancy A, Antignac M, Minoletti C, Dijols S, Mouries V, Duong NT, Battioni P, Dansette PM, Mansuy D. Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry 1999; 38: 14264-14270
14. Niwa T, Fujimoto M, Kishimoto K, Yabusaki Y, Ishibashi F, Katagiri M. Metabolism and interaction of bisphenol A in human hepatic cytochrome P450 and steroidogenic CYP17. Biol Pharm Bull 2001; 24: 1064-1067
15. Marill J, Cresteil T, Lanotte M, Chabot GG. Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol 2000; 58: 1341-1348
16. Bort R, Castell JV, Pfeifer A, Gomezlechon MJ, Mace K. High expression of human CYP2C in immortalized human liver epithelial cells. Toxicol Vitro 1999; 13: 633-638
17. Wu J, Dong H, Cai Z, Yu Y. Stable expression of human cytochrome CYP2B6 and CYP1A1 in chinese hamster CHL cells: their use in micronucleus assays. Chin Med Sci J 1997; 12: 148-155
18. Yan LQ, Yu YN, Zhuge J, Xie HY. Cloning of human cytochrome P450 2A6 cDNA and its expression in mammalian cells. Zhongguo Yaolixue Yu Dulixue Zazhi 2000; 14: 31-35
19. Chen Q, Wu J, Yu Y. Establishment of transgenic cell line CHL-3A4 and its metabolic activation. Zhonghua Yufang Yixue Zazhi 1998; 32: 281-284
20. Zhu GJ, Yu YN, Li X, Qian YL. Cloning of cytochrome P450- 2C9 cDNA from human liver and its expression in CHL cells. World J Gastroenterol 2002; 8: 318-322
21. Li X, Yu YN, Zhu GJ, Qian YL. Cloning of UGTTA9 cDNA from liver tissues and its expression in CHL cells. World J Gastroenterol 2001; 7: 841-845
22. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning, A Laboratory Manual; 2nd ed. New York: Cold Spring Habor Laboratory Press 1989; 6: 28-29
23. Johannesen KA, De Pierre JW. Measurement of cytochrome P-450 in the presence of large amounts of contaminating hemoglobin and methemoglobin. Anal Biochem 1978; 86: 725-732
24. Ho JW, Moody DE. Determination of tolbutamide hydroxylation in rat liver microsomes by high-performance liquid chromatography: effect of psychoactive drugs on in vitro activity. Life Sci 1993; 52: 21-28
25. Kaminsky LS, de-Morais SM, Faletto MB, Dunbar DA, Goldstein JA. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol 1993; 43: 234-239
26. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33: 1743-1752
27. Komai K, Sumida K, Kaneko H, Nakatsuka I. Identification of a new non-functional CYP2C18 allele in Japanese: Substitution of T204 to A in exon 2 generates a premature stop codon. Pharmacogenetics 1996; 6: 117-119
28. Tsuneoka Y, Matsuo Y, Okuyama E, Watanabe Y, Ichikawa Y. Genetic analyis of the cytochrome P-450IIC18 (CYP2C18) gene and a novel member of the CYP2C subfamily. FEBS Lett 1996; 384: 281-284
29. Correia MA, Farrell GC, Schmid R, Ortiz-de-Montellano PR, Yost GS, Mico BA. Incorporation of exogenous heme into hepatic cytochrome P-450 in vivo. J Biol Chem 1979; 254: 15-17
30. Zaphiropoulos PG. Exon skipping and circular RNA formation in transcripts of the human cytochrome P-450 2C18 gene in epidermis and of the rat androgen binding protein gene in testis. Mol Cell Biol 1997; 17: 2985-2993
31. Klose TS, Blaisdell JA, Goldstein JA. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 1999; 13: 289-295
32. Niwa T, Sato R, Yabusaki Y, Ishibashi F, Katagiri M. Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica 1999; 29: 187-193
33. Jounaidi Y, Hecht JE, Waxman DJ. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res 1998; 58: 4391-4401
34. Minoletti C, Dijols S, Dansette PM, Mansuy D. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18. Biochemistry 1999; 38: 7828-7836
35. Miners JO, Birkett DJ. Cytochrome P450 2C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525-538
36. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ. Tolbutamide hydroxylation by human liver microsomes. Biochem Pharmacol 1988; 37: 1137-1144
37. Easterbrook J, Fackett D, Li AP. A comparison of arclor 1254-induced and uninduced rat liver microsomes to human liver microsomes in phenytoin O-deethylation, coumarin 7-hydroxylation, tolbutamide 4-hydroxylation, S-mephengtoin 4′-hgdroxg lation, chloroxazone 6-hydroxylation and testosterone 6beta-hydroxylation. Chem Biol Interact 2001; 134: 243-249
38. Zaphiropoulos PG. Mechanisms of pre-mRNA splicing: classical versus non-classical pathways. Histol Histopathol 1998; 13: 585-589
39. Zaphiropoulos PG. RNA molecules containing exons originating from different members of the cytochrome P450 2C gene subfamily (CYP2C) in human epidermis and liver. Nucleic Acids Res 1999; 27: 2585-2590
40. Finta C, Zaphiropoulos PG. The human CYP2C locus: a prototype for intergenic and exon repetition splicing events. Genomics 2000; 63: 433-438
41. Warner SC, Finta C, Zaphiropoulos PG. Intergenic transcripts containing a novel human cytochrome P450 2C exon 1 spliced to sequences from the CYP2C9 gene. Mol Biol Evol 2001;18:1841-1848
42. Finta C, Zaphiropoulos PG. Intergenic mRNA molecules resulting from trans-splicing. J Biol Chem 2002; 277: 5882-5890
43. Finta C, Zaphiropoulos PG. A statistical view of genome transcription? J Mol Evol 2001; 53: 160-162